Drug intelligence / Profile preview

anti-CLL1-CD33-NKG2D bicephalic CAR-T cells

Development stage: Phase 2
Lead developer: Xuzhou Medical University
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Anti-CLL1-CD33-NKG2D bicephalic CAR-T cells is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy being developed by Xuzhou Medical University for the treatment of relapsed or refractory acute myeloid leukemia (AML). This multi-targeted therapy is designed to simultaneously recognize three distinct antigens expressed on AML cells: C-type lectin-like molecule-1 (CLL1), CD33, and ligands for the NKG2D receptor. By targeting multiple markers, the therapy aims to enhance the elimination of leukemia cells and reduce the risk of immune escape caused by antigen loss, a common challenge in single-target CAR-T therapies. The treatment involves collecting a patient's T cells via apheresis, genetically engineering them to express the specific CARs, and reinfusing them into the patient following lymphodepletion. It is currently being evaluated in Phase I/II clinical trials.

Other names: anti-CLL1-CD33-NKG2D Bicephali CAR-T cellsanti-CLL-1-CD33-NKG2D Bicephali CAR-T cellsanti-CLL 1-CD33-NKG2D Bicephali CAR-T cellsanti-CLL1-CD33-NKG2D bicephalic CAR-T cells-Xuzhou Medical University-acute myeloid leukemiaanti-CLL-1-CD33-NKG2D bicephalic CAR-T cells-Xuzhou Medical University-acute myeloid leukemiaanti-CLL 1-CD33-NKG2D bicephalic CAR-T cells-Xuzhou Medical University-acute myeloid leukemia

Targets

MICB (Major histocompatibility complex class i-related protein B)CD33 (Myeloid cell surface antigen CD33)CLEC12A

Beyond the preview

Go deeper on anti-CLL1-CD33-NKG2D bicephalic CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CLL1-CD33-NKG2D bicephalic CAR-T cells.

Explore the full profile